NCT04499157

Effect of MEMOPTIC on Visual Field of Patients Followed for a Chronic Open-angle Glaucoma

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Centre Hospitalier Universitaire, Amiens · Academic / Other
• Sex: All
• Age: 20 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Open-angle glaucoma is a degeneration of the optic nerve, highlighted by campimetric alterations, and wose only current therapeutic target is the lowering of the intra-ocular pressure (using eye drops, surgery or laser). MEMOPTIC is a tablet combining citicoline, magnesium and Gingko biloba, which have a neuroprotective effect already used in neurodegenerative diseases such as Alzheimer's disease for example. Citicoline has also shown several promising results in ophthalmological diseases (glaucoma, amblyopia or more recently in ischemic optic neuropathies). The citicoline used in eye drops (NEURODROP) has already shown results on the preservation of the vision of glaucomatous patients. The purpose of this project is to determine if MEMOPTIC can have an effect, in addition to the conventional treatments, in the preservation of vision of patients treated for an open-angle glaucoma.

Conditions

• Open-angle Glaucoma
• Visual Field

Interventions

Type	Name	Description
DRUG	MEMOPTIC	Patients will receive their usual treatment of glaucoma adding 1 tablet of MEMOPTIC per day during 2 years of following
DRUG	usual treatment of glaucoma	Patients will receive only their usual treatment of glaucoma.

Timeline

• Start date: 2020-08-01
• Primary completion: 2023-08-01
• Completion: 2023-08-01
• First posted: 2020-08-05
• Last updated: 2023-02-08

Locations

1 site across 1 country: France